Entheon Biomedical Announces Corporate Update Including Investment in Wonder Scientific

Shares :

0
(0)

Vancouver, British Columbia–(Newsfile Corp. – December 4, 2020) – Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (“Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces a strategic investment in Wonder Scientific Inc. (“Wonder Scientific”).

Wonder Scientific’s team of University Researchers and Product Development experts create custom, naturally derived, active pharmaceutical ingredients (APIs) to supply the growing global clinical and commercial demand for psychedelics. 

Entheon’s first strategic investment provides exposure in other verticals of the psychedelic therapy space and strategic access to psychoactive pharmaceutical ingredients and scientific bench strength as Entheon develops therapeutic treatments for addiction. 

“Our investment in Wonder Scientific is part of our strategy in gaining low risk exposure to other segments of the regulated psychedelic treatment space,” said Timothy Ko. “Their team of experienced pharmacologists and product experts enhances a strategic relationship providing opportunities for additional revenues from the company’s line of genetics, bio-stimulants, and pharmaceuticals.”

Tegan Adams, President & Founder of Wonder Scientific, commented on the partnership: “We are absolutely thrilled and privileged to have our value and strategy highlighted and recognized by Entheon management. We look forward to upcoming collaborations and a profitable symbiotic relationship.”

Entheon is pleased to announce it has entered into an investor relations consulting agreement with Mr. Joseph Cullen.

Mr. Cullen’s career has included over five years of public market experience, primarily focused on the resource and technology sectors with an emphasis on investor relations and corporate finance. His previous experience also includes working for Deloitte and VMWare, as well as co-founding and managing private ventures in the financial services, environmental consultancy, and technology sectors. Mr. Cullen is being paid $5000 per month for a one-year term. 

Further, pursuant to its stock option plan, the Company has granted options to purchase up to 3,175,000 common shares in the Company (the “Options”) to certain officers, directors and consultants of the Company. The Options are exercisable at $0.71 per share for a period of five years from the date of grant. Of the Options, 2,725,000 are subject to vesting over a 2-year term. The Options have been granted under and are governed by the terms of the Company’s incentive stock option plan.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective N,N-dimethyltryptamine based psychedelic therapeutic products (“DMT Products“) for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.

About Wonder Scientific

Wonder’s vision is to help the world find it’s Wonder again. Wonder’s mission is to unlock the healing properties of hundreds of new plant medicines sourced from diverse locations, transforming them into regulated pharmaceutical products for global commercialization and sales.

For more information, please contact the Company at:

Entheon Biomedical Corp.
Joseph Cullen, Investor Relations 
Telephone: +1 (778) 919-8615
joe@entheonbiomedical.com
https://entheonbiomedical.com/

For media inquiries, please contact Crystal Quast at:

Bullseye Corporate
Crystal Quast
Telephone: +1 (647) 529-6364
Quast@BullseyeCorporate.com

Sign up for MORE news updates !


This article is written and published by The Cannabis Stock


Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.

Click on a star to rate this article !

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.


Shares :